# Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects

> **NCT03402178** · PHASE1 · TERMINATED · sponsor: **Eisai Co., Ltd.** · enrollment: 118 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** E2082
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03402178
- **Lead sponsor:** Eisai Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-21
- **Primary completion:** 2020-02-20
- **Final completion:** 2020-02-20
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Safety Review
- **Last updated:** 2021-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03402178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03402178, "Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03402178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*